Nivolumab
DDR Gene Mutation
Lantern Pharma Inc.monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the DDR Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib Lantern Pharma Inc. | Phase 1/2 | CCC |
(-)-Hydroxyurea methylacylfulvene Lantern Pharma Inc. | Phase 1/2 | CCC |
Ipilimumab Lantern Pharma Inc. | Phase 1/2 | CCC |
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →